Abstract:Background: Clinically nonfunctional pituitary adenomas (NFPAs) without any clinical elevation of hormone and with a difficulty in its early-stage diagnosis are highly heterogeneous with different hormone expressions in NFPA tissues, including luteinizing hormone (LH)-positive, follicle-stimulating hormone (FSH)-positive, LH/FSH-positive, and negative (NF). Elucidation of molecular mechanisms and discovery of biomarkers common and specific to those different subtypes of NFPAs will benefit NFPA patients in early-stage diagnosis and individualized treatment.Methods: Two-dimensional gel electrophoresis (2DGE) and PDQuest image analyses were used to compare proteomes of different NFPA subtypes (NF-, LH-, FSH-, and LH/FSH-positive) relative to control pituitaries (Con). Differentially expressed proteins (DEPs) were characterized with mass spectrometry (MS). Each set of DEPs in four NFPA subtypes was evaluated with overlap analysis and signaling pathway network analysis with comparison to determine any DEP and pathway network that are common and specific to each NFPA subtype.Results: A total of 93 differential protein-spots were determined with comparison of each NFPA type (NF-, LH-, FSH-, and LH/FSH-positive) versus control pituitaries. A total of 76 protein-spots were MS-identified (59 DEPs in NF vs. Con; 65 DEPs in LH vs. Con; 63 DEPs in FSH vs. Con; and 55 DEPs in LH/FSH vs. Con). A set of DEPs and pathway network data were common and specific to each NFPA subtype. Four important common pathway systems included MAPK-signaling abnormality, oxidative stress, mitochondrial dysfunction, and cell-cycle dysregulation. However, these pathway systems were, in fact, different among four NFPA subtypes with different protein-expression levels of most of nodes, different protein profiles, and different pathway network profiles.Conclusions: These result data demonstrate that common and specific DEPs and pathway networks exist in four NFPA subtypes, and clarify proteome heterogeneity of four NFPA subtypes. Those findings will help to elucidate molecular mechanisms of NFPAs, and discover protein biomarkers to effectively manage NFPA patients towards personalized medicine.

Quantitative Proteomic Profiling Identifies Differentially Regulated Pathways in Fanconi Anemia and Aplastic Anemia

Proteomic Analysis for Identifying the Differences in Molecular Profiling Between Fanconi Anaemia and Aplastic Anaemia.

Proteomic Profiling and Bioinformatics Analysis Identify Key Regulators During the Process from Fanconi Anemia to Acute Myeloid Leukemia

Mutation Spectrum, Expression Profiling, and Prognosis Evaluation of Fanconi Anemia Signaling Pathway Genes for 4259 Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia

Identification of Immune Infiltration, Differentially Expressed Genes, and Signaling Pathways in Fanconi Anemia Based on Bioinformatics Analysis

Identification of novel biomarkers differentially expressed between African-American and Caucasian-American prostate cancer patients

Identifying an AML Prognostic Model Using 10 Marker Genes from Single-Cell Transcriptome and Bulk Transcriptome Analysis

Functional analysis of Fanconi anemia mutations in China.

Comprehensive Analysis on Phenotype and Genetic Basis of Chinese Fanconi Anemia Patients: Dismal Outcomes Call for Nationwide Studies

Deciphering the Core Metabolites of Fanconi Anemia by Using a Multi-Omics Composite Network

Phenotypic and Genotypic Correlation Evaluation of 148 Pediatric Patients with Fanconi Anemia in a Chinese Rare Disease Cohort.

Unmanipulated Haploidentical Haematopoietic Cell Transplantation with Radiation-Free Conditioning in Fanconi Anaemia: A Retrospective Analysis from the Chinese Blood and Marrow Transplantation Registry Group

TMT-based Comprehensive Proteomic Profiling Identifies Serum Prognostic Signatures of Acute Myeloid Leukemia

Distinct Metabolic Signature of Human Bladder Cancer Cells Carrying an Impaired Fanconi Anemia Tumor-Suppressor Signaling Pathway

[Association between clinical outcome and gene mutation in children with Fanconi anemia].

Comparative Proteomic Analysis of Human Lung Adenocarcinoma A549 and A549/DDP Cells

Heterogeneity Analysis of the Proteomes in Clinically Nonfunctional Pituitary Adenomas

Proteomic profiles of patients with atrial fibrillation provide candidate biomarkers for diagnosis

Polyclonal Evolution of Fanconi Anemia to MDS and AML Revealed at Single Cell Resolution.

Deciphering the role of post-translational modifications in fanconi anemia proteins and their influence on tumorigenesis

Bone Marrow Failure in Fanconi Anemia: Clinical and Genetic Spectrum in a Cohort of 20 Pediatric Patients